Document is current
Any future updates will be listed below
-
Authors
Vilar-Ribó, Laura https://orcid.org/0000-0001-8758-523X
Cabana-Domínguez, Judit https://orcid.org/0000-0002-4732-7284
Alemany, Silvia https://orcid.org/0000-0002-7925-6767
Llonga, Natalia https://orcid.org/0000-0003-4325-6201
Arribas, Lorena
Grau-López, Lara
Daigre, Constanza
Cormand, Bru https://orcid.org/0000-0001-5318-4382
Fernàndez-Castillo, Noèlia
Ramos-Quiroga, Josep Antoni https://orcid.org/0000-0003-1622-0350
Soler Artigas, María https://orcid.org/0000-0002-3213-1107
Ribasés, Marta https://orcid.org/0000-0003-1039-1116
- License Information
-
More Information
Article History
Received: 26 May 2023
Revised: 9 May 2024
Accepted: 10 May 2024
First Online: 29 May 2024
Competing interests
: J.A.R.Q was on the speakers’ bureau and/or acted as a consultant for Biogen, Idorsia, Janssen-Cilag, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, BMS, Medice, Rubió, Uriach, Technofarma, and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Idorsia, Janssen-Cilag, Rubió, Takeda, Bial, and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Exeltis, Idorsia, Janssen-Cilag, Neuraxpharm, Oryzon, Roche, Probitas, Psious, and Rubió. All other authors declare no biomedical financial interests or conflicts of interest.
